Carboximaltosa férrica - Evidencia Clínica

Existe una amplia evidencia clínica con Carboximaltosa Férrica: 29 ensayos clínicos aleatorizados.

Referencias

ONCOLOGY
Hedenus M et al. Intravenous Ferric Carboxymaltose As Sole Anemia Therapy In Patients With Lymphoid Malignancies, Chemotherapy-Induced Anemia and Functional Iron Deficiency. ASH 2013 Congress December 7-10, New Orleans, LA, USA.

GYNECOLOGY
Breymann C et al. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008 Apr;101(1):67-73.
Van Wyck DB et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007 Aug;110(2 Pt 1):267-78.
Van Wyck DB et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009 Dec;49(12):2719-28.
Seid MH et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008 Oct;199(4):435.e1-7.
Seid MHand Chatwani, A. Ferric Carboxymaltose for the Treatment of Anemia in Heavy Uterine Bleeding and Postpartum Women. Submitted for publication .
Favrat et al., 17th European Haematology Association Congress, Amsterdam, The Netherlands, June 14-17 2012.

NEPHROLOGY
Beshara S et al. Pharmacokinetics and red cell utilization of 52Fe/59Fe-labelled iron polymaltose in anaemic patients using positron emission tomography. Br J Haematol. 2003 Mar;120(5):853-9.
Covic A and Mircescu G. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrol Dial Transplant 2010; doi: 10.1093/ndt/gfq069.
Qunibi WY et al. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant 2011; 26: 1599-1607.
Bailie GR et al. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Hemodial Int. 2010 Jan;14(1):47-54.
Charytan C et al. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrol Dial Transplant. 2013 Apr;28(4):953-64.
Onken JE et al. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol Dial Transplant. 2013 Aug 20.
Evenepoel et al. American society of Nephrology – Kidney Week. October 27-November 1 2009, San Diego, CA, USA.
Benjamin et al. American society of Nephrology – Kidney Week. November 16-21 2010, Denver, CO, USA.

CARDIOLOGY
Anker SD et al. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron . Eur J Heart Fail. 2009 Nov;11(11):1084-91.
Anker SD et al. Ferric Carboxymaltose in patients with heart failure and iron deficiency. NEJM. 2009; 361.
Arutyunov GP, Bylova NA, Ivleva AY, Kobalava ZD. The safety of intravenous (i.v.) ferric carboxymaltose versus i.v. iron sucrose in patients with chronic heart failure (CHF) and chronic kidney disease (CKD) with iron deficiency (ID). Eur J Heart Fail 2009;8(Suppl. 2). Abstract presented at the European society of Cardiology – Heart Failure 2008 Congress, June 14-17, Milan, Italy.

GASTROENTEROLOGY
Geisser P et al. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschung. 2010;60(6a):373-85.
Kulnigg S et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol. 2008 May;103(5):1182-92.
Evstatiev R et al. FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011 Sep;141(3):846-853.e1-2.
Evstatiev R et al. Ferric carboxymaltose prevents recurrence of anemia in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar;11(3):269-77.
Kulnigg S et al. Iron Deficiency Generates Secondary Thrombocytosis and Platelet Activation in IBD: the Randomized, Controlled ThromboVIT Trial Inflamm Bowel Dis 2013 published online DOI 10.1097/MIB.0b013e318281f4db.

NEUROLOGY
Allen RP et al. Clinical efficacy and safety of IV ferric carboxymaltose (FCM) treatment of RLS: a multi-centred, placebo-controlled preliminary clinical trial. Sleep Med. 2011 Oct;12(9):906-13.

MIXED
Geisser P. Arzneim Forsch Drug Res 2010a.
Barish CF et al. Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials. Anemia. 2012;2012:172104. Epub 2012 Sep 10.
Hussain I et al. Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron eficiency Anemia. Anemia. 2013;2013:169107. doi: 10.1155/2013/169107. Epub 2013 Aug 29.
Onken JR et al. Appendix to A Multi-center, Randomized, Active-controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Iron Deficiency Anemia. Transfusion. 2013 Jun 17. doi: 10.1111/trf.12289.

Más Información: Ver Ficha Técnica de Carboximaltosa Férrica